Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00140205 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Leptin Administration During Fasting
A Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00140205 is a Phase 1 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 15 participants.
The verdict
NCT00140205, a Phase 1 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study will be to determine the correct dose of leptin, a natural hormone secreted by the fat cells, to give to people when they are fasting and also to determine whether giving leptin to a person when he or she is fasting will reverse the changes in hormone levels that occur with fasting.
Interventions
- DRUG r-metHuLeptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2001-02 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00140205
The ClinicalTrials.gov registry entry for NCT00140205 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which r-metHuLeptin is the first listed.
NCT00140205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00140205 about?
NCT00140205 is a clinical study titled "Pharmacokinetics of Leptin Administration During Fasting". The purpose of this study will be to determine the correct dose of leptin, a natural hormone secreted by the fat cells, to give to people when they are fasting and also to determine whether giving leptin to a person when he or she is fasting will reverse the changes in hormone levels that occur with...
What is the current status of trial NCT00140205?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2001-02. Estimated completion is 2016-12.
What interventions are being tested in trial NCT00140205?
The interventions under investigation include: r-metHuLeptin (DRUG).
Who is sponsoring clinical trial NCT00140205?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.